Hepatitis C Community
Phase I Study New Hep C Drug for Peg/RBV Nonresponders
About This Community:

This forum is for questions about medical issues and research aspects of Hepatitis C such as, questions about being newly diagnosed, questions about current treatments, information and participation in discussions about research studies and clinical trials related to Hepatitis. If you would like to communicate with other people who have been touched by Hepatitis, please visit our new Hepatitis Social/Living with Hepatitis forum

Font Size:
A
A
A
Background:
Blank
Blank
Blank
Blank Blank

Phase I Study New Hep C Drug for Peg/RBV Nonresponders

Anyone interested in joining a study for the evaluation of a new drug....pls read details below:
Related Discussions
7 Comments Post a Comment
Blank
Avatar_n_tn
Phase I Study New Hep C Drug for Peg/RBV Nonresponders

Peregrine Pharmaceuticals' anti-viral Phase 1 trial is designed to evaluate the safety of escalating doses of Tarvacin in patients with chronic Hepatitis C virus infection.

Below is a summary of the trial parameters:

Tarvacin is a monoclonal antibody designed for solid-tumor cancers.
http://www.tarvacin.com

Protocol Title:
A Phase I Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Tarvacin™) in Patients Chronically Infected with Hepatitis C Virus (HCV) who are Non-responders or Relapsers after Treatment with Pegylated Interferon plus Ribavirin

Contact Information
Karen Roberts, MS      714.508.6035    ***@****

PHASE I STUDY SITE  
Bach & Godofsky, MD, PA, Bradenton,  Florida,  34205,  United States; Recruiting
Mickey Mays, RNMS, ARNP  941-746-2711  Ext. 39
Eliot W Godofsky, MD,  Principal Investigator

Phase: I
Indications: Chronic Hepatitis C virus (HCV) Infection

Objectives:
--Determine safety and tolerability
--Characterize blood pharmacokinetics and viral kinetics
--Define the maximum tolerated dose (MTD) and/or maximum effective dose (MED)

Selected Eligibility Criteria:
    
Inclusion
--Must be 18 years of age
--Chronic HCV infection based on medical history and detectable serum HCV RNA

--Failure to respond to or relapse after treatment with pegylated interferon plus ribavirin

Exclusion
--No prior exposure to any chimeric antibody
--No decompensated clinical liver disease or cirrhosis or other cause of liver disease such as alcoholic liver disease
--No uncontrolled intercurrent disease
--No requirement for chronic daily treatment with NSAIDs, anti-platelet drugs or steroids
--Must not be pregnant or nursing
--No prior thrombotic or hemorrhagic disorders



--------------------------------------------------------------------------------


_______________________________________________
NATAP nataphcv mailing list -- ***@****

Blank
Avatar_f_tn
thanks for the details, Ben. Someone gave us a preview on an 8/8 thread, I wonder if they got their 30 subjects by now? I think it was mentioned that they were looking for 30 individuals, or did I imagine that one?
Blank
Avatar_n_tn
Get tested for hepatitis C



--------------------------------------------------------------------------------
Otros Titulares
  Som
Blank
Avatar_f_tn
is that the LOLA article?
Cin
Blank
Avatar_n_tn

Affirmative!
Blank
Avatar_f_tn
Thanks!
Cin
Blank
Avatar_n_tn

You very welcome...
Blank
Post a Comment
To
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis C Community Resources
RSS Expert Activity
233488_tn?1310696703
Blank
New Cannabis Article from NORTH Mag...
Jul 20 by John C Hagan III, MD, FACS, FAAOBlank
242532_tn?1269553979
Blank
3 Reasons Why You are Still Binge E...
Jul 14 by Roger Gould, M.D.Blank
242532_tn?1269553979
Blank
Emotional Eating: What Your Closet ...
Jul 09 by Roger Gould, M.D.Blank
Top Hepatitis Answerers
Avatar_f_tn
Blank
dontworry_behappy1
163305_tn?1333672171
Blank
orphanedhawk
Rural Mural, CA
Avatar_f_tn
Blank
nan535
Brooklyn, NY
446474_tn?1404424777
Blank
HectorSF
CA
1815939_tn?1377995399
Blank
pooh55811
96938_tn?1189803458
Blank
FlGuy
South, FL